MX2009009816A - Anticuerpos monoclonales para el tratamiento del cancer. - Google Patents

Anticuerpos monoclonales para el tratamiento del cancer.

Info

Publication number
MX2009009816A
MX2009009816A MX2009009816A MX2009009816A MX2009009816A MX 2009009816 A MX2009009816 A MX 2009009816A MX 2009009816 A MX2009009816 A MX 2009009816A MX 2009009816 A MX2009009816 A MX 2009009816A MX 2009009816 A MX2009009816 A MX 2009009816A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
monoclonal antibodies
therapeutics
treating
Prior art date
Application number
MX2009009816A
Other languages
English (en)
Inventor
Ugur Sahin
Oezlem Tuereci
Michael Koslowski
Original Assignee
Ganymed Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ganymed Pharmaceuticals Ag filed Critical Ganymed Pharmaceuticals Ag
Publication of MX2009009816A publication Critical patent/MX2009009816A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)

Abstract

La presente invención proporciona anticuerpos útiles como agentes terapéuticos para el tratamiento y/o prevención de enfermedades asociadas con la expresión celular de GT468, incluyendo enfermedades relacionadas con tumores como el cáncer de seno, cáncer de pulmón, cáncer gástrico, cáncer de ovarios y cáncer hepatocelular.
MX2009009816A 2007-03-14 2008-03-14 Anticuerpos monoclonales para el tratamiento del cancer. MX2009009816A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89486007P 2007-03-14 2007-03-14
EP07005258A EP1970384A1 (en) 2007-03-14 2007-03-14 Monoclonal antibodies for treatment of cancer
PCT/EP2008/002063 WO2008110379A2 (en) 2007-03-14 2008-03-14 Monoclonal antibodies for treatment of cancer

Publications (1)

Publication Number Publication Date
MX2009009816A true MX2009009816A (es) 2009-11-23

Family

ID=38134942

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009816A MX2009009816A (es) 2007-03-14 2008-03-14 Anticuerpos monoclonales para el tratamiento del cancer.

Country Status (25)

Country Link
US (4) US8354104B2 (es)
EP (3) EP1970384A1 (es)
JP (2) JP5389675B2 (es)
KR (2) KR20150080032A (es)
CN (2) CN105131115A (es)
AU (1) AU2008226001B2 (es)
BR (1) BRPI0808814A2 (es)
CA (1) CA2678732C (es)
CY (1) CY1120123T1 (es)
DK (1) DK2125897T3 (es)
ES (1) ES2664571T3 (es)
HR (1) HRP20180485T1 (es)
HU (1) HUE037671T2 (es)
IL (1) IL200388A (es)
LT (1) LT2125897T (es)
MX (1) MX2009009816A (es)
NO (1) NO2125897T3 (es)
NZ (1) NZ579614A (es)
PL (1) PL2125897T3 (es)
PT (1) PT2125897T (es)
RS (1) RS57089B1 (es)
SG (1) SG10201506625VA (es)
SI (1) SI2125897T1 (es)
WO (1) WO2008110379A2 (es)
ZA (1) ZA200905833B (es)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8961980B2 (en) 2007-03-14 2015-02-24 Ganymed Pharmaceuticals Ag Monoclonal antibodies for treatment of cancer
US8975375B2 (en) 2005-09-12 2015-03-10 Ganymed Pharmaceuticals Ag Identification of tumor-associated antigens for diagnosis and therapy
US9216218B2 (en) 2010-03-23 2015-12-22 Ganymed Pharmaceuticals Ag Monoclonal antibodies for treatment of cancer

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP2166021A1 (en) * 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
AU2015205868B2 (en) * 2008-09-16 2017-04-27 Ganymed Pharmaceuticals Ag Monoclonal antibodies for treatment of cancer
DK3026064T3 (en) 2011-05-13 2019-01-14 Ganymed Pharmaceuticals Gmbh ANTIBODIES FOR TREATMENT OF CANCER EXPRESSING CLAUDIN 6
WO2014146672A1 (en) * 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
CN106659785B (zh) * 2014-05-07 2021-04-30 武田有限公司 包含gm-csf中和化合物的液体制剂
CN108779497B (zh) * 2016-03-14 2022-08-02 库雷梅塔治疗有限责任公司 足糖萼蛋白和tra-相关抗体、制备方法和作为抗癌治疗剂的用途
TW201900213A (zh) * 2017-05-27 2019-01-01 美商免疫醫療公司 免疫球蛋白ａ陽性細胞的調節
WO2023220336A1 (en) * 2022-05-13 2023-11-16 Herzlinger Regina E Methods, systems, and apparatus for administering an antibody treatment via infusion

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5744585A (en) 1995-03-16 1998-04-28 Medenica; Rajko D. Human monoclonal antibody against lung carcinoma
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US20020065394A1 (en) * 1998-03-18 2002-05-30 Kenneth Jacobs Secreted proteins and polynucleotides encoding them
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9826143D0 (en) 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
WO2002006329A2 (en) 2000-07-18 2002-01-24 Curagen Corporation Human polynucleotides and polypeptides encoded thereby
AU2001284703B2 (en) 2000-08-03 2007-03-22 Therapeutic Human Polyclonals Inc. Production of humanized antibodies in transgenic animals
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
PT1354034E (pt) 2000-11-30 2008-02-28 Medarex Inc Roedores transgénicos transcromossómicos para produção de anticorpos humanos
US20020177547A1 (en) 2001-01-16 2002-11-28 Karin Molling Pharmaceutical compositions for treating or preventing cancer
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
EP1478772A2 (en) 2001-08-14 2004-11-24 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
AU2003209459A1 (en) * 2002-03-06 2003-09-16 Hybrigenics Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11
WO2003102159A2 (en) 2002-06-04 2003-12-11 Curagen Corporation Novel proteins and nucleic acids encoding same
US7053201B2 (en) 2002-08-30 2006-05-30 National Defense Medical Center Nucleic acid molecules and polypeptides related to h-ADAM7
MXPA05004022A (es) 2002-10-17 2005-10-05 Genmab As Anticuerpos monoclonales humanos contra cd20.
CN101245376A (zh) 2003-01-17 2008-08-20 香港中文大学 作为妊娠相关病症的诊断标志物的循环mRNA
US20050255114A1 (en) 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
CN1663603A (zh) 2004-03-02 2005-09-07 北京大学 一种肿瘤－胎盘抗原蛋白及其dna在肿瘤治疗中的应用
EP1762575A1 (en) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP1970384A1 (en) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2166021A1 (en) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2221063A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
FI2398902T3 (fi) 2009-02-20 2023-11-28 Astellas Pharma Inc Menetelmiä ja koostumuksia syövän diagnoosia ja hoitoa varten
EP2371864A1 (en) * 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8975375B2 (en) 2005-09-12 2015-03-10 Ganymed Pharmaceuticals Ag Identification of tumor-associated antigens for diagnosis and therapy
US9919036B2 (en) 2005-09-12 2018-03-20 Ganymed Pharmaceuticals Ag Identification of tumor-associated antigens for diagnosis and therapy
US8961980B2 (en) 2007-03-14 2015-02-24 Ganymed Pharmaceuticals Ag Monoclonal antibodies for treatment of cancer
US9475867B2 (en) 2007-03-14 2016-10-25 Ganymed Pharmaceuticals Ag Monoclonal antibodies for treatment of cancer
US10125196B2 (en) 2007-03-14 2018-11-13 Ganymed Pharmaceuticals Ag Monoclonal antibodies for treatment of cancer
US9216218B2 (en) 2010-03-23 2015-12-22 Ganymed Pharmaceuticals Ag Monoclonal antibodies for treatment of cancer
US10596256B2 (en) 2010-03-23 2020-03-24 TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH Monoclonal anti-GT 468 antibodies for treatment of cancer

Also Published As

Publication number Publication date
HRP20180485T1 (hr) 2018-05-18
US10125196B2 (en) 2018-11-13
SI2125897T1 (en) 2018-06-29
JP2010520910A (ja) 2010-06-17
SG10201506625VA (en) 2015-10-29
US9475867B2 (en) 2016-10-25
DK2125897T3 (en) 2018-04-23
NZ579614A (en) 2012-02-24
CA2678732A1 (en) 2008-09-18
RS57089B1 (sr) 2018-06-29
KR20150080032A (ko) 2015-07-08
WO2008110379A8 (en) 2009-11-05
AU2008226001B2 (en) 2013-09-05
US20100111975A1 (en) 2010-05-06
KR101567494B1 (ko) 2015-11-23
AU2008226001A1 (en) 2008-09-18
JP5389675B2 (ja) 2014-01-15
NO2125897T3 (es) 2018-06-16
LT2125897T (lt) 2018-04-25
CA2678732C (en) 2017-12-19
CN101754979A (zh) 2010-06-23
US20130156782A1 (en) 2013-06-20
ES2664571T3 (es) 2018-04-20
EP2125897A2 (en) 2009-12-02
WO2008110379A3 (en) 2008-10-30
ZA200905833B (en) 2011-02-23
PT2125897T (pt) 2018-03-29
EP1970384A1 (en) 2008-09-17
JP2013255506A (ja) 2013-12-26
CN105131115A (zh) 2015-12-09
BRPI0808814A2 (pt) 2015-06-23
CN101754979B (zh) 2015-04-08
IL200388A0 (en) 2010-04-29
CY1120123T1 (el) 2018-12-12
EP2487189A1 (en) 2012-08-15
JP5843822B2 (ja) 2016-01-13
EP2487189B1 (en) 2018-08-22
IL200388A (en) 2015-08-31
EP2487189B8 (en) 2019-01-09
US20170058044A1 (en) 2017-03-02
HUE037671T2 (hu) 2018-09-28
US8961980B2 (en) 2015-02-24
US20150175686A1 (en) 2015-06-25
KR20100014405A (ko) 2010-02-10
US8354104B2 (en) 2013-01-15
WO2008110379A2 (en) 2008-09-18
EP2125897B1 (en) 2018-01-17
PL2125897T3 (pl) 2018-09-28

Similar Documents

Publication Publication Date Title
MX2009009816A (es) Anticuerpos monoclonales para el tratamiento del cancer.
EP4242236A3 (en) Monoclonal antibodies against claudin-18 for treatment of cancer
SG10201903351SA (en) Monoclonal antibodies against claudin-18 for treatment of cancer
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
IL258880A (en) Compounds of diarylhydantoin
MX2020001224A (es) Anticuerpos para el tratamiento del cancer.
MX2020011768A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2020011771A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2020011790A (es) Anticuerpos especificos para claudina 6 (cldn6).
MX357010B (es) Anticuerpos monoclonales para tratamiento de cancer.
NZ607588A (en) Antibodies against human TWEAK and uses thereof
MX2012012901A (es) Metodos para tratamiento de condiciones relacionadas con interleucina-1beta.
EP4364756A3 (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2009124281A3 (en) Novel antibodies against cancer target block tumor growth, angiogenesis and metastasis
NZ589795A (en) Use of LM-1 antibody which binds to NONO/nmt55 protein to prevent metastasis

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration